Related Experiment Video
Updated: Jul 11, 2025

Comparative Lesions Analysis Through a Targeted Sequencing Approach
Published on: November 5, 2019
Multiomic sequencing of paired primary and metastatic small bowel carcinoids
Mackenzie D Postel1, Sourat Darabi2, James R Howe3
1Institute of Translational Genomics, Keck School of Medicine of USC, Los Angeles, CA, USA.
Abstract:
Background: Small bowel carcinoids are insidious tumors that are often metastatic when diagnosed. Limited mutation landscape studies of carcinoids indicate that these tumors have a relatively low mutational burden. The development of targeted therapies will depend upon the identification of mutations that drive the pathogenesis and metastasis of carcinoid tumors. Methods: Whole exome and RNA sequencing of 5 matched sets of normal tissue, primary small intestine carcinoid tumors, and liver metastases were investigated. Germline and somatic variants included: single nucleotide variants (SNVs), insertions/deletions (indels), structural variants, and copy number alterations (CNAs). The functional impact of mutations was predicted using Ensembl Variant Effect Predictor. Results: Large-scale CNAs were observed including the loss of chromosome 18 in all 5 metastases and 3/5 primary tumors. Certain somatic SNVs were metastasis-specific; including mutations in ATRX, CDKN1B, MXRA5 (leading to the activation of a cryptic splice site and loss of mRNA), SMARCA2, and the loss of UBE4B. Additional mutations in ATRX, and splice site loss of PYGL, leading to intron retention observed in primary and metastatic tumors. Conclusions: We observed novel mutations in primary/metastatic carcinoid tumor pairs, and some have been observed in other types of neuroendocrine tumors. We confirmed a previously observed loss of chromosome 18 and CDKN1B. Transcriptome sequencing added relevant information that would not have been appreciated with DNA sequencing alone. The detection of several splicing mutations on the DNA level and their consequences at the RNA level suggests that RNA splicing aberrations may be an important mechanism underlying carcinoid tumors.
Insights
Small bowel carcinoid tumors have low mutation rates, but specific genetic alterations, including chromosome 18 loss and splicing mutations, drive their metastasis. Identifying these key mutations is crucial for developing targeted therapies.
Area of Science:
- Oncology
- Genetics
- Molecular Biology
Background:
- Small bowel carcinoid tumors are often diagnosed at a metastatic stage.
- These neuroendocrine tumors exhibit a low overall mutational burden.
- Understanding the genetic drivers of carcinoid pathogenesis and metastasis is essential for targeted therapy development.
Purpose of the Study:
- To identify novel mutations driving the development and spread of small bowel carcinoid tumors.
- To compare the genomic and transcriptomic profiles of primary tumors and their metastases.
Main Methods:
- Whole exome and RNA sequencing were performed on 5 matched pairs of normal tissue, primary carcinoid tumors, and liver metastases.
- Analysis included single nucleotide variants (SNVs), insertions/deletions (indels), structural variants, and copy number alterations (CNAs).
- Functional impact of mutations was predicted using Ensembl Variant Effect Predictor.
Main Results:
- Loss of chromosome 18 was consistently observed in metastases and frequently in primary tumors.
- Metastasis-specific somatic SNVs were identified in genes including ATRX, CDKN1B, MXRA5, SMARCA2, and UBE4B.
- Splicing mutations affecting MXRA5 and PYGL were detected, leading to altered mRNA and intron retention.
Conclusions:
- Novel mutations in primary and metastatic carcinoid tumors were identified, with some overlap with other neuroendocrine tumors.
- The study confirmed previously reported chromosome 18 and CDKN1B alterations.
- RNA sequencing provided critical insights, highlighting RNA splicing aberrations as a potential key mechanism in carcinoid tumor development.

